ANLN and hepatocellular carcinoma: Indeed, these findings using the RNA methylation inhibitor DZNeP 33, showed that DZNeP inhibits ANLN m6A methylation and effectively attenuates the malignant phenotype and BM in vivo of HCC cells exhibiting ANLN overexpression.